MX2012014579A - Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos. - Google Patents

Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.

Info

Publication number
MX2012014579A
MX2012014579A MX2012014579A MX2012014579A MX2012014579A MX 2012014579 A MX2012014579 A MX 2012014579A MX 2012014579 A MX2012014579 A MX 2012014579A MX 2012014579 A MX2012014579 A MX 2012014579A MX 2012014579 A MX2012014579 A MX 2012014579A
Authority
MX
Mexico
Prior art keywords
treating
methods
estrogen
related diseases
dhea
Prior art date
Application number
MX2012014579A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of MX2012014579A publication Critical patent/MX2012014579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Procedimientos para tratar o reducir la probabilidad de adquirir enfermedades relacionadas con estrógenos (p. ej., agravadas por estrógenos), incluida la endometriosis, que incluyen administrar a una paciente un modulador selectivo del receptor de estrógenos (SERM) en combinación con inhibición de secreciones ováricas, por ejemplo administrando un agonista o un antagonista de LHRH. En algunas realizaciones, también se administra un precursor de esteroides sexuales, seleccionándose dicho precursor del grupo que consiste en dehidroepiandrosterona (DH EA), dehidroepiandrosterona sulfato (DHEA-S), androst-5-eno-3ß, 1 7-diol (5-diol) y androstenodiona o un compuesto transformado en uno de estos.
MX2012014579A 2010-06-16 2011-06-16 Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos. MX2012014579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35546510P 2010-06-16 2010-06-16
PCT/CA2011/000709 WO2011156908A1 (en) 2010-06-16 2011-06-16 Methods of treating or preventing estrogen-related diseases

Publications (1)

Publication Number Publication Date
MX2012014579A true MX2012014579A (es) 2013-05-22

Family

ID=45329203

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014579A MX2012014579A (es) 2010-06-16 2011-06-16 Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.

Country Status (14)

Country Link
US (1) US11576891B2 (es)
EP (1) EP2582371B1 (es)
JP (3) JP2013528626A (es)
KR (9) KR20130031339A (es)
CN (2) CN107693794A (es)
AU (1) AU2011267798B2 (es)
BR (1) BR112012032189B1 (es)
CA (1) CA2802761C (es)
EA (1) EA026675B1 (es)
IL (1) IL225146A (es)
MX (1) MX2012014579A (es)
SG (1) SG186333A1 (es)
WO (1) WO2011156908A1 (es)
ZA (1) ZA201209323B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505856A (ja) 2011-12-16 2015-02-26 オレマ ファーマシューティカルズ インク． 新規のベンゾピラン化合物、その組成物および使用
CA2928131C (en) 2012-10-24 2023-02-07 The Board Of Trustees Of The University Of Illinois Benzothiophene derivatives and use thereof for treating estrogen-related medical disorders
EP2911660B1 (en) 2012-10-24 2019-12-04 The Board of Trustees of the University of Illionis Compositions and methods for treating estrogen-related medical disorders
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2016106146A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
AU2017312499B2 (en) * 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
PT3518933T (pt) 2016-09-30 2022-05-10 Takeda Pharmaceuticals Co Métodos de tratamento de fibroides uterinos e endometriose
WO2019136147A1 (en) * 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors
IL296196A (en) * 2020-03-05 2022-11-01 Abbvie Inc Methods of administering elagolix
CN111830169B (zh) * 2020-07-24 2022-07-12 中山大学 多囊卵巢综合征诊断的化合物及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2617646C2 (de) 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4481190A (en) 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5204337A (en) 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
IL92496A0 (en) 1988-12-01 1990-08-31 Schering Corp Compositions for transdermal delivery of estradiol
HU221589B (hu) 1989-03-10 2002-11-28 Endorecherche Inc. Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5461065A (en) 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US5484798A (en) 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6391892B1 (en) 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
GB2303628A (en) 1995-07-27 1997-02-26 Lilly Co Eli 5-Hydroxy- and 5-phenyl-substituted 1-[4-(aminoalkoxy)phenyl]-2-phenylbenzene derivatives for the treatment of post menopausal symptoms and intermediates
US5811421A (en) 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
US5726186A (en) 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
BR9706966A (pt) 1996-01-11 1999-05-04 Novo Nordisk As Utilização do enanciômero-l de um composto e processo para tratamento ou profilaxia de câncer da mama
CA2241623A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
IT1289068B1 (it) * 1996-01-24 1998-09-25 Sandro Tasoniero Impianto automatico per la stiratura e lo scarico di capi di abbigliamento
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
CA2244675A1 (en) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
TW442286B (en) 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1997032837A1 (fr) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Derives estrogenes non steroidiens
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
DE69707189T2 (de) 1996-04-19 2002-06-20 American Home Prod Östrogene Verbindungen
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CN1879630A (zh) 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
JP2003137814A (ja) * 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US20050159361A1 (en) * 2002-03-11 2005-07-21 Takahito Hara Remedies for sex hormone-dependent disease
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
EP1709023B1 (en) 2004-01-22 2009-11-11 Eli Lilly And Company Selective estrogen receptor modulators
EP1713820A1 (en) 2004-01-22 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
EP1709022A1 (en) 2004-01-22 2006-10-11 Eli Lilly And Company Selective estrogen receptor modulators
EP1713770A1 (en) 2004-01-29 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women

Also Published As

Publication number Publication date
KR20200144591A (ko) 2020-12-29
ZA201209323B (en) 2014-04-30
KR20190042762A (ko) 2019-04-24
BR112012032189B1 (pt) 2020-11-03
AU2011267798B2 (en) 2015-04-02
CA2802761A1 (en) 2011-12-22
EA026675B1 (ru) 2017-05-31
AU2011267798A1 (en) 2013-01-10
KR20170127044A (ko) 2017-11-20
SG186333A1 (en) 2013-01-30
CN107693794A (zh) 2018-02-16
US11576891B2 (en) 2023-02-14
EA201300019A1 (ru) 2013-05-30
JP6532754B2 (ja) 2019-06-19
JP2017210490A (ja) 2017-11-30
CA2802761C (en) 2017-01-03
KR20150039882A (ko) 2015-04-13
IL225146A (en) 2017-03-30
KR20150139626A (ko) 2015-12-11
JP2015147809A (ja) 2015-08-20
US20110312925A1 (en) 2011-12-22
BR112012032189A2 (pt) 2016-11-22
KR101731008B1 (ko) 2017-04-27
CN103037862A (zh) 2013-04-10
KR20220061258A (ko) 2022-05-12
EP2582371B1 (en) 2019-10-16
KR20160088947A (ko) 2016-07-26
EP2582371A1 (en) 2013-04-24
KR20130031339A (ko) 2013-03-28
WO2011156908A1 (en) 2011-12-22
JP2013528626A (ja) 2013-07-11
KR20140089402A (ko) 2014-07-14
EP2582371A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
MX2012014579A (es) Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.
AR117670A2 (es) Modulador del receptor de andrógeno y sus usos
EA201200369A1 (ru) Применение предшественников половых стероидных гормонов в комбинации с селективным модулятором эстрогеновых рецепторов для лечения заболеваний и состояний у постменопаузных женщин
MX2015012430A (es) Esteroides neuroactivos y metodos para su uso.
MX2017013565A (es) Ligandos degradadores selectivos del receptor androgénico (sard) y sus métodos uso.
BR112014031910A2 (pt) formulações e terapias naturais de combinação para reposição hormonal
MX366325B (es) Terapia de combinacion.
MY161059A (en) Progesterone antagonists such as cdb-4214 in the treatment of embodimetriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
MX365818B (es) Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
MA32981B1 (fr) Regime posologique pour un agoniste du recepteur s1p
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
UA102587C2 (ru) Применение композиции для лечения тяжелой и неконтролируемой астмы
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
ME01122B (me) Jedinjenja i postupci za liječenje raka dojke
WO2009138186A3 (de) SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN
TN2014000059A1 (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
JO3128B1 (ar) بيبرازينو-3-فينيل-اندانيس معالج بالديتوريوم لمعالجة انفصام الشخصية- 1
JP2013500324A5 (es)
BR112012023281A2 (pt) composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.